孫鑫 1 , 李幼平 12 , 黃鷗寧 3 , 何運昉 3 , 沈驥 4 , 鄺璞 5
  • 1. 四川大學華西醫(yī)院衛(wèi)生部移植工程與移植免疫重點實驗室2. 四川大學華西醫(yī)院中國循證醫(yī)學中心成都,6100413. 四川省廣元市410醫(yī)院,廣元,6280174. 四川省衛(wèi)生廳5. 四川大學華西臨床醫(yī)學院;

背景 　廣元市410醫(yī)院于2003年2月、4月分兩批共收治6例SARS確診病人,至今已治愈5例,4月25日成為四川SARS定點醫(yī)院.
目的 　評價SARS定點醫(yī)院防治費用及對醫(yī)院收入和運作的影響.方法:從定點醫(yī)院的觀點,以治愈率為臨床效果指標,回顧性評價SARS確診和疑似病人的治療費用,定點醫(yī)院總體防治的費用,SARS定點醫(yī)院對總體、醫(yī)療和藥品收入,門診和住院就診病人的影響.敏感性分析評價院內感染和治愈率的變化對費用的影響.
結果 　5例確診,6例疑似病人均治愈.人均治療費用分別為7866和4273元,醫(yī)療費用分別為14983.86和5494.92元.除藥物支持治療外,其余各項費用在確診和疑似病人間無統(tǒng)計學意義.SARS定點醫(yī)院總體防治費用為174.45萬元.指定為定點醫(yī)院前后,醫(yī)院收入和門診、住院人數(shù)分別下降33.45%,43.62%和47.33%.
結論 　SARS確診病人費用為14983.86元.定點醫(yī)院將明顯影響醫(yī)院收入和運作.

引用本文： 孫鑫,李幼平,黃鷗寧,何運昉,沈驥,鄺璞. 嚴重急性呼吸綜合征(SARS)定點醫(yī)院防治費用評價及對醫(yī)院經(jīng)濟的影響. 中國循證醫(yī)學雜志, 2003, 03(2): 135-141. doi: 復制

1. ［1］Jefferson T, Dernicheli V, Deeks J, Rivetti D Neuraminidase in hibitors for preventing and treating influenza in healthy adults CSR [M/CD] CL 2003 - 1.
2. ［2］Donald R. Husereau, B. Sc. Pharm M. Sc. 1 Bruce Brady , M. A ,M. Sc. 1 Allison McGeer MD, FRCPC2Oseltamivir for the treeatment of suspected influenza a clinical and economic assessmeont[R]. CCOHTA Issue 21 2001.
3. ［3］Burls A, Clark W, Stewart T, Preston C, Bryan S, Jefferson T,et al. Zanamivir [or the treatment of influenza in adults: a system atic review and economie evaluation. HTA 2002; 6 (9). NHS R&D HTA Programme.
4. ［4］Full Guidance on the the use of zanamivir, oseltamivir and amantadine for the treatment of influenza Tecbnology Appraisal Guidance No. 58 [S] NHS February 2003.
5. ［5］Do neuraminidase inhibitors prevent influenza [R] CCOHTA. Issue 27 November 2001.
6. ［6］Treating influenza by medication - Zanamivir SBU Alert May 22,2001.
7. ［7］Gideon Koren, Susan King, Sandra Knowles, Elizabeth PhillipsRibavirin in the treatment of SARS: A new trick for auold drug [J]? JAMC 13 MAI 2003; 168 (10).
8. ［8］Jefferson TO, Tyrrell D Antivirals for the Common Cold CSR [M/CD]CL 2003- 1.
9. ［9］Randolph AG, Wang EEL Ribavirin for respiratory syncytial virns infection of the lower respiratory tract CSR [ M/CD ] CL 2003-1.
  1. 1. ［1］Jefferson T, Dernicheli V, Deeks J, Rivetti D Neuraminidase in hibitors for preventing and treating influenza in healthy adults CSR [M/CD] CL 2003 - 1.
  2. 2. ［2］Donald R. Husereau, B. Sc. Pharm M. Sc. 1 Bruce Brady , M. A ,M. Sc. 1 Allison McGeer MD, FRCPC2Oseltamivir for the treeatment of suspected influenza a clinical and economic assessmeont[R]. CCOHTA Issue 21 2001.
  3. 3. ［3］Burls A, Clark W, Stewart T, Preston C, Bryan S, Jefferson T,et al. Zanamivir [or the treatment of influenza in adults: a system atic review and economie evaluation. HTA 2002; 6 (9). NHS R&D HTA Programme.
  4. 4. ［4］Full Guidance on the the use of zanamivir, oseltamivir and amantadine for the treatment of influenza Tecbnology Appraisal Guidance No. 58 [S] NHS February 2003.
  5. 5. ［5］Do neuraminidase inhibitors prevent influenza [R] CCOHTA. Issue 27 November 2001.
  6. 6. ［6］Treating influenza by medication - Zanamivir SBU Alert May 22,2001.
  7. 7. ［7］Gideon Koren, Susan King, Sandra Knowles, Elizabeth PhillipsRibavirin in the treatment of SARS: A new trick for auold drug [J]? JAMC 13 MAI 2003; 168 (10).
  8. 8. ［8］Jefferson TO, Tyrrell D Antivirals for the Common Cold CSR [M/CD]CL 2003- 1.
  9. 9. ［9］Randolph AG, Wang EEL Ribavirin for respiratory syncytial virns infection of the lower respiratory tract CSR [ M/CD ] CL 2003-1.